GET DAILY SIGNALSGRI Bio (GRI) Climbs +11.9% Over 30 Days on Clinical Momentum and Analyst Support
Key Takeaways
- GRI Bio (GRI) shares rose approximately 11.9% over the trailing 30 days, from a closing price of $1.68 on October 8, 2026 to $1.88 on November 6, 2026.
- The advance was punctuated by a sharp single-session gain of roughly 21.3% on November 6, reflecting the high volatility typical of clinical-stage micro-cap biotech names.
- H.C. Wainwright reiterated a Buy rating and a $10 price target in mid-October, pointing to Bristol Myers Squibb's Phase 3 IPF data as validating the idiopathic pulmonary fibrosis category.
- The lead candidate, GRI-0621, an oral therapy for idiopathic pulmonary fibrosis, remains the central value driver following positive Phase 2a data reported in early September.
- Broader analyst consensus is a Strong Buy with an average 12-month price target of $18.50, though estimates vary widely given the stock's small size and thin liquidity.
- As a pre-revenue biotechnology company, GRI's share price is driven primarily by clinical readouts, financing events, and analyst sentiment rather than fundamentals tied to revenue or earnings.
- For additional detail, investors can review GRI Bio's Price Targets, Earnings, and Forecast pages.
GRI Bio (GRI) Company Overview and Market Position
GRI Bio, Inc. is a La Jolla, California-based clinical-stage biopharmaceutical company focused on developing immune cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases. Its platform targets Natural Killer T (NKT) cells, which act earlier in the inflammatory cascade, with the goal of interrupting disease progression and restoring the immune system to homeostasis.
The company's lead program, GRI-0621, is an oral RARβγ agonist and type 1 invariant NKT cell inhibitor being developed for idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease with significant unmet need. A second candidate, GRI-0803, is a type 2 NKT cell agonist advancing through IND-enabling studies for autoimmune indications such as systemic lupus erythematosus and multiple sclerosis. The company also maintains a proprietary library of more than 500 compounds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow GRI primarily for the clinical trajectory of GRI-0621 and the company's ability to secure additional capital.
GRI Bio (GRI) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, GRI shares moved from a closing price of $1.68 on October 8, 2026 to $1.88 on November 6, 2026, a gain of approximately 11.9%. The period was uneven: the stock declined through mid-October to the low $1.30s before recovering through late October and early November, culminating in a roughly 21.3% single-session surge on November 6.
Over the trailing quarter, the picture is one of pronounced volatility. The stock traded near $1.47 in early August, climbed to an intraday high around $3.36 in early September, pulled back into the mid-$1.30s by mid-October, and subsequently recovered toward $1.88. This multi-month swing reflects the outsized price action characteristic of a low-float clinical-stage biotech company whose shares are sensitive to data catalysts and shifts in sentiment.
What Drove GRI Stock Price in the Last 30 Days
The recent advance was supported by renewed analyst attention. In mid-October, H.C. Wainwright reiterated a Buy rating and a $10 price target on GRI Bio, citing data from Bristol Myers Squibb's Phase 3 ALOFT-IPF trial of admilparant as validating the broader IPF opportunity. The firm's commentary framed GRI-0621's differentiated mechanism within a category gaining clinical momentum.
Separately, GRI Bio held its 2026 Annual Meeting of Stockholders on November 4, at which shareholders elected two directors, ratified the company's auditor, and approved an expansion of the equity incentive plan. While governance-related, such events can influence sentiment for a thinly traded name. It is worth noting that the sharp November 6 advance was not accompanied by a company-specific announcement, and outsized daily moves in micro-cap biotech often occur on thin trading volumes. A counterpoint to the bullish view came from Weiss Ratings, which reiterated a Sell (E+) rating in mid-October.
What Drove GRI Stock Performance Over the Last Quarter
The broader quarterly trend has been shaped by clinical progress in the company's lead program. In early September, GRI Bio reported positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis, showing a favorable placebo-adjusted change in forced vital capacity and no serious treatment-emergent adverse events in the treated arm. This followed U.S. Food and Drug Administration Orphan Drug Designation granted in June 2026 and additional translational biomarker data reinforcing the therapy's mechanism.
Alongside clinical momentum, financing activity has been a recurring theme. The company reported cash of approximately $10.9 million at June 30, 2026 and has stated that existing resources are expected to fund operations into 2027, while also disclosing substantial doubt about its ability to continue as a going concern without additional capital. This combination of clinical validation and persistent financing risk helps explain the stock's wide trading range over the quarter.
GRI Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape GRI Bio's share price going forward. The company's third-quarter 2026 earnings report is expected in mid-November, with analysts anticipating a narrower loss than in the prior-year period; updates on cash runway, operating expenses, and any additional financing plans will be closely watched. Progress on GRI-0621, including next steps toward a registration-enabling development path, and the advancement of GRI-0803 through IND-enabling studies represent key clinical catalysts.
Investors should also monitor analyst price-target revisions, broader sector sentiment around IPF treatments, and any developments related to Nasdaq listing requirements and future capital raises, which carry dilution risk. As with all early-stage biotechnology companies, clinical trial outcomes, regulatory decisions, and financing conditions will ultimately determine the stock's trajectory, and these carry substantial inherent risk. From what I see, this is important because the next few months could bring meaningful updates on both clinical and financial fronts.
Using Tickeron AI Tools for Biotech Research
In my own analysis, I frequently turn to Tickeron’s Trending AI Robots page to review curated AI-driven trading strategies across thousands of tickers. The selection highlights top-performing bots with details on approaches, timeframes, and metrics, which helps me compare systematic options that align with different risk levels. It offers a practical way to explore data-driven tools without sifting through everything manually.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GRI saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for GRI moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 34 similar instances where the indicator exited the overbought zone. In 33 of the 34 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for GRI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
GRI broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRI entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GRI's RSI Oscillator exited the oversold zone, 47 of 54 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on GRI as a result. In 78 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for GRI just turned positive on October 27, 2026. Looking at past instances where GRI's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
GRI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +31.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRI advanced for three days, in 184 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.042) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. GRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement